See Search Box
lower down this column for searches of Finfacts news pages. Where there may be
the odd special character missing from an older page, it's a problem that
developed when Interactive Tools upgraded to a new content management system.
Finfacts is Ireland's leading business information site and
you are in its business news section.
US biotechnology giant Amgen and the Irish Government today announced the start
of a $200 million-plus expansion programme in Ireland that is expected to result
in the creation of 100 jobs. The Taoiseach, Enda Kenny T.D. and the Tánaiste,
Eamon Gilmore T.D. officiated at the groundbreaking ceremony today, marking the
commencement of a major construction programme at the Amgen plant at Pottery
Road, in Dún Laoghaire,
Co Dublin. The investment is supported by the Irish Government through IDA
The $200-plus million expansion programme will include the construction of an
approximately 11,700 square metres building extension, new production plant,
expanded warehouse and the major refurbishment of the existing buildings. In
addition, a significant research and development investment will also see the
Dun Laoghaire facility undergo a major technology process enhancement to
transform the plant into one of the leading biotechnology manufacturing sites in
Today’s announcement comes almost a year after Amgen purchased the former Pfizer
plant in Dún
Laoghaire, resulting in the continuation of all 280 jobs at the site. The
expansion will result in the creation of up to 100 new roles within Amgen, in
addition to approximately 350 construction jobs during the 19-month building
period. Recruitment for the Amgen positions has already commenced, and many
more will be employed in a contract capacity.
The San Francisco Chronicle
reports that George B. Rathmann, whose passion for science and business
helped build Amgen into the world's largest biotechnology company, died Sunday
at home in Palo Alto, California. He was 84.
Dr. Rathmann, widely regarded as one of the fathers of the biotech industry,
had been treated for kidney failure for several years and died of pneumonia, his
son James Rathmann said.
Part of his treatment included a version of EPO (or Epogen), one of the drugs
that turned Amgen into a biotech powerhouse.
Check out our new
subscription service, Finfacts Premium
, at a low annual charge of €25 - - if
you are a regular user of Finfacts, 50 euro cent a week is hardly a huge ask to
support the service.
It's a simple fact that in the
prevailing economic climate, the provision of high quality content cannot be
sustained through advertising alone.
Business executives who put a
premium on time and value high quality information, should use our service.